Literature DB >> 9142319

Optimization of transfection of human endothelial cells.

M Teifel1, L T Heine, S Milbredt, P Friedl.   

Abstract

Recently developed transfection methods for mammalian cells provide a powerful means for the study of gene function. Unfortunately, human endothelial cells were relative refractory to the classic transfection techniques. In this study we compared the usability of calcium phosphate, DEAE-dextran transfection, transferrinfection, lipofection, and electroporation for the transfection of early passage HUVECs and for the human endothelial cell lines ECV 304 and EA.hy 926. The classic transfection methods resulted in no or only marginal expression of the reporter gene E. coli beta-galactosidase. For lipofection experiments we compared the commercially available liposome formulations DOTAP and Transfectam with liposomes prepared of dimethyldioctadecylammoniumbromide (DDAB) or 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide (DMRIE) as the cationic lipid compound and dioleylphosphatidylethanolamine (DOPE) or Azolectin (a crude fraction of soybean lipids, commercially available as phosphatidylcholine II) as neutral co-lipid. Because the protocol for the chemical synthesis of DMRIE has not been published yet, we developed a protocol for the chemical synthesis of this cationic lipid. With transfection protocols optimized for each cell line, we could achieve transfection efficiencies up to 2%. Compared to the other methods used, the lipofection proved to be a reliable technique for the efficient transfection of the human endothelial cell lines ECV 304 and EA.hy 926. Although we achieved a maximum transfection efficiency of 0.45% for the lipofection of HUVEC, the electroporation seemed to be the better choice for these cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9142319     DOI: 10.3109/10623329709044156

Source DB:  PubMed          Journal:  Endothelium        ISSN: 1026-793X


  8 in total

1.  Transference of recombinant VE-cadherin cytoplasmic domain alters endothelial junctional integrity and porcine microvascular permeability.

Authors:  Mingzhang Guo; Mack H Wu; Harris J Granger; Sarah Y Yuan
Journal:  J Physiol       Date:  2004-01-01       Impact factor: 5.182

2.  Optimizing transfection of primary human umbilical vein endothelial cells using commercially available chemical transfection reagents.

Authors:  Michelle A Hunt; Margaret J Currie; Bridget A Robinson; Gabi U Dachs
Journal:  J Biomol Tech       Date:  2010-07

3.  Lipoplex formulation of superior efficacy exhibits high surface activity and fusogenicity, and readily releases DNA.

Authors:  Rumiana Koynova; Yury S Tarahovsky; Li Wang; Robert C MacDonald
Journal:  Biochim Biophys Acta       Date:  2006-11-01

4.  Expression of 5-lipoxygenase in pulmonary artery endothelial cells.

Authors:  Ying-Yi Zhang; Jennifer L Walker; Annong Huang; John F Keaney; Clary B Clish; Charles N Serhan; Joseph Loscalzo
Journal:  Biochem J       Date:  2002-01-15       Impact factor: 3.857

Review 5.  Physical non-viral gene delivery methods for tissue engineering.

Authors:  Adam J Mellott; M Laird Forrest; Michael S Detamore
Journal:  Ann Biomed Eng       Date:  2012-10-26       Impact factor: 3.934

6.  Hydrophobic moiety of cationic lipids strongly modulates their transfection activity.

Authors:  Rumiana Koynova; Boris Tenchov; Li Wang; Robert C Macdonald
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

7.  Phosphate-buffered saline-based nucleofection of primary endothelial cells.

Authors:  Jinjoo Kang; Swapnika Ramu; Sunju Lee; Berenice Aguilar; Sathish Kumar Ganesan; Jaehyuk Yoo; Vijay K Kalra; Chester J Koh; Young-Kwon Hong
Journal:  Anal Biochem       Date:  2008-12-25       Impact factor: 3.365

8.  Transfection efficiency and cytotoxicity of nonviral gene transfer reagents in human smooth muscle and endothelial cells.

Authors:  Karin Kiefer; Jule Clement; Patrick Garidel; Regine Peschka-Süss
Journal:  Pharm Res       Date:  2004-06       Impact factor: 4.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.